
Pharma companies were able to negotiate far fewer so-called ‘pay to delay’ cases as a strategy to stave off generic …

Authorities in the US claim that AbbVie and Teva filed ‘sham’ lawsuits in a complicated pay-to-delay case for generic forms …
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion

